Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

The Rapidly Evolving Standard of Care: Focus on the Role, Benefit, and Toxicity of New Therapies in Non-Small Cell Lung Cancer


Description:
The purpose of this activity is to educate pharmacists on the efficacy, toxicity, and place in therapy for the new lung cancer drugs.  The talk will cover the pivotal study data for new agents and discuss how they fit in the current guidelines as well as go over toxicity prevention and treatment.
 
Objectives: 
1. Identify the appropriate place in therapy for new targeted agents and how they compare to the
   standard treatment.
2. Describe common and unique toxicities associated with targeted therapies.
3. Recommend appropriate toxicity prevention and treatment measures for new targeted therapies to
    optimize outcomes.
 
This recorded activity is a based on a live program that was offered on October 14, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.25

CE Units

0.125

Activity Type

  • Knowledge Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Discloures:
The presenter is Val R. Adams, PharmD, BCOP, FCCP; Associate Professor, Pharmacy Program Director, PGY2, Specialty Residency, Hematology/Oncology, University of Kentucky College of Pharmacy, Lexington, KY
Dr. Adams does not have any relevant financial relationships with any commercial interests   
     
The reviewer is Steven L. D'Amato, RPh, BSPharm; Executive Director, New England Cancer Specialists; President of the Association of Community Cancer Centers; Clinical Associate Professor, Tufts University School of Medicine 
Mr. D'Amato does not have any relevant financial relationships with any commercial interests      
 
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The purpose of this activity is to educate pharmacists on the efficacy, toxicity, and place in therapy for the new lung cancer drugs.  The talk will cover the pivotal study data for new agents and discuss how they fit in the current guidelines as well as go over toxicity prevention and treatment.
 

Objectives

  • Identify the appropriate place in therapy for new targeted agents and how they compare to the standard treatment.
  • Describe common and unique toxicities associated with targeted therapies.
  • Recommend appropriate toxicity prevention and treatment measures for new targeted therapies to optimize outcomes.

Speaker(s)/Author(s)

Val R. Adams, PharmD, FCCP, BCOP picture

Val R. Adams, PharmD, FCCP, BCOP
Associate Professor, Pharmacy Program Director, PGY2, Specialty Residency, Hematology/Oncology, University of Kentucky College of Pharmacy


Brief Bio : Dr. Adams is an Associate Professor in the department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center where he has a clinical practice site. As the director of the hematology / oncology residency program, he has trained thirty one residents and maintains an active research lab. He received his B.S. in pharmacy from the University of Utah and received his doctor of pharmacy from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology / oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship he joined the University of Kentucky faculty in 1996.

Activity Number

0280-0000-16-086-H01-P

Release Date: Nov 22, 2016
Credit Expiration Date: Nov 22, 2018

CE Hours

1.25